Prudential PLC Reduces Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Key Points

• Prudential PLC has reduced its holdings in Regeneron Pharmaceuticals by 50.3%, now owning 1,726 shares worth approximately $1.095 million.
• Several hedge funds, including Capital International Investors and Pacer Advisors Inc., have significantly increased their stakes in Regeneron Pharmaceuticals, reflecting strong institutional interest in the company.
• Regeneron reported $12.89 EPS for the last quarter, exceeding analysts' expectations and experiencing 3.6% revenue growth year-over-year.

Prudential PLC decreased its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 50.3% during the 1st quarter, according to the company in its most recent disclosure with the SEC. The fund owned 1,726 shares of the biopharmaceutical company's stock after selling 1,745 shares during the quarter. Prudential PLC's holdings in Regeneron Pharmaceuticals were worth $1,095,000 as of its most recent filing with the SEC.

Other hedge funds also recently made changes to their positions in the company. Capital International Investors boosted its stake in shares of Regeneron Pharmaceuticals by 41.6% during the fourth quarter. Capital International Investors now owns 4,736,929 shares of the biopharmaceutical company's stock worth $3,373,859,000 after buying an additional 1,390,534 shares during the period. GAMMA Investing LLC boosted its stake in shares of Regeneron Pharmaceuticals by 89,825.0% during the first quarter. GAMMA Investing LLC now owns 815,620 shares of the biopharmaceutical company's stock worth $517,291,000 after buying an additional 814,713 shares during the period. Price T Rowe Associates Inc. MD boosted its stake in shares of Regeneron Pharmaceuticals by 63.5% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 2,085,447 shares of the biopharmaceutical company's stock worth $1,485,527,000 after buying an additional 810,144 shares during the period. Nuveen LLC acquired a new stake in shares of Regeneron Pharmaceuticals during the first quarter worth about $343,764,000. Finally, Pacer Advisors Inc. boosted its stake in shares of Regeneron Pharmaceuticals by 2,296.9% during the first quarter. Pacer Advisors Inc. now owns 407,370 shares of the biopharmaceutical company's stock worth $258,366,000 after buying an additional 390,374 shares during the period. Hedge funds and other institutional investors own 83.31% of the company's stock.

Analyst Upgrades and Downgrades

Several equities research analysts have recently weighed in on REGN shares. Canaccord Genuity Group reiterated a "buy" rating and set a $850.00 target price on shares of Regeneron Pharmaceuticals in a research note on Wednesday, July 23rd. UBS Group reiterated a "neutral" rating on shares of Regeneron Pharmaceuticals in a research note on Friday, August 1st. Robert W. Baird decreased their target price on shares of Regeneron Pharmaceuticals from $759.00 to $652.00 and set a "neutral" rating for the company in a research note on Friday, April 25th. Redburn Atlantic upgraded shares of Regeneron Pharmaceuticals to a "strong-buy" rating in a research note on Thursday. Finally, Cantor Fitzgerald began coverage on shares of Regeneron Pharmaceuticals in a research report on Tuesday, April 22nd. They issued an "overweight" rating and a $695.00 price objective for the company. One research analyst has rated the stock with a sell rating, seven have given a hold rating, seventeen have issued a buy rating and three have issued a strong buy rating to the company. Based on data from MarketBeat.com, Regeneron Pharmaceuticals has an average rating of "Moderate Buy" and an average target price of $838.00.

Regeneron Pharmaceuticals Trading Up 2.6%

Shares of REGN opened at $580.41 on Friday. The company has a debt-to-equity ratio of 0.09, a current ratio of 4.60 and a quick ratio of 3.72. The firm has a 50 day simple moving average of $544.21 and a 200-day simple moving average of $595.53. Regeneron Pharmaceuticals, Inc. has a 1-year low of $476.49 and a 1-year high of $1,211.20. The stock has a market cap of $61.52 billion, a price-to-earnings ratio of 14.63, a price-to-earnings-growth ratio of 1.89 and a beta of 0.33.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last issued its quarterly earnings data on Friday, August 1st. The biopharmaceutical company reported $12.89 earnings per share for the quarter, topping analysts' consensus estimates of $8.43 by $4.46. Regeneron Pharmaceuticals had a net margin of 31.37% and a return on equity of 15.06%. The business had revenue of $3,675,600 billion during the quarter, compared to analysts' expectations of $3.30 billion. During the same period last year, the company posted $11.56 EPS. The company's revenue was up 3.6% on a year-over-year basis. Equities analysts forecast that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current fiscal year.

Regeneron Pharmaceuticals Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Wednesday, September 3rd. Shareholders of record on Monday, August 18th will be paid a $0.88 dividend. This represents a $3.52 annualized dividend and a yield of 0.6%. The ex-dividend date of this dividend is Monday, August 18th. Regeneron Pharmaceuticals's payout ratio is presently 8.87%.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.

Want to see what other hedge funds are holding REGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.